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Introduction
 
The field of complex disease genetics has witnessed rapid
progress over the past few months. The advent of genome-wide
association scans (GWAS) has mediated a change in gear and
the Type 2 diabetes (T2D) research community has set an unpre-
cedented record with five genome-wide association studies
published since February 2007 [1–6], increasing the number
of confirmed Type 2 diabetes susceptibility loci from three
(
 
PPARG
 
, 
 
KCNJ11
 
, 
 
TCF7L2
 
) to nine (with the addition of
 
CDKAL1
 
, 
 
CDKN2A
 
/
 
B
 
, 
 
IGF2BP2
 
, 
 
HHEX
 
/
 
IDE
 
, 
 
FTO
 
  and
 
SLC30A8
 
). These studies have increased our understanding of
the genetic aetiology of T2D and provided invaluable insights
into the way genetic studies should be conducted. This review
aims to summarize the major findings distilled from the dawn
of this new era in T2D genetics.
The feasibility of carrying out GWAS has been eagerly
anticipated in the field of T2D genetics for some time. Several
years of mostly unsuccessful gene hunting led to the realiza-
tion that carefully designed and conducted, large-scale,
biology-agnostic studies would be a necessary addition to the
geneticist’s arsenal. Whole genome linkage scans, candidate
gene-focused association studies and region-specific fine-
mapping approaches had dominated the literature over the
past few years. However, only three genes (
 
PPARG
 
, 
 
KCNJ11
 
and, more recently, 
 
TCF7L2
 
) had been established as T2D
susceptibility loci [7–9]. Several reasons can account for the
paucity of success stories in the scientific literature, but the big-
gest culprits stand out as insufficient power, over-interpretation
of results and candidacy assessments based on incomplete
knowledge of T2D aetiopathology. Lack of power in genetic
association studies could be ascribed to a variety of factors,
including insufficient sample sizes to detect the modest effects
conferred by susceptibility variants, as well as an incomplete
understanding of human genetic variation. Indeed, it was not
unusual for gene mapping studies to examine only a handful of
variants, or even a single variant, per gene (most likely in a
coding portion of the transcribed unit).
 
Setting the stage for genome-wide studies
 
Evolution of our understanding of the human genome has
been made possible by the development of high-throughput
genotyping technologies, enabling endeavours such as the
International HapMap project [10]. The HapMap has given us
insights into common variation genome-wide by cataloguing
single nucleotide polymorphisms (SNPs), their frequencies and
pairwise linkage disequilibrium (LD) relationships in samples
from four populations. In addition, emerging evidence of the
putatively important role of non-protein-coding DNA (as
exemplified by conserved non-coding regions and microRNAs)
[11,12] have dictated a shift in focus from gene-centric to
genome-wide examination of human variation. High-throughput
genotyping technologies have now become an affordable reality,
allowing the genome-wide profiling of large-scale, well-phenotyped
samples, which are also becoming increasingly available (and
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which will be necessary to detect the moderate effects that T2D
susceptibility variants are expected to confer).
Two main commercially available platforms for genome-wide
SNP genotyping have been used by the five published T2D
association scans to date: the Affymetrix 500k and the
Illumina HumanHap300 arrays. The fixed SNP content on
these chips has been differently selected. Variants on the
Affymetrix 500k platform have been selected to provide an
approximately random distribution of SNPs across the
genome, without taking LD patterns into account. In contrast,
the Illumina HumanHap300 chip contains approximately
317k SNPs, specifically selected to tag common variation [as
defined by a minor allele frequency (MAF) > 5%], making use
of pairwise correlation information between HapMap phase I
SNPs in the European-descent CEU sample. Pairwise evaluations
of the proportion of variation captured on the basis of
HapMap phase II indicate that both the Affymetrix and Illumina
platforms provide good coverage of common SNPs genome-
wide in a single experiment (65% and 75%, respectively) [13,14].
Each platform balances different advantages and limitations.
For example, the Affymetrix chip captures a smaller proportion
of common variation genome-wide, but is not population
specific and has inbuilt redundancy (as ascribed by the LD-
agnostic design), thus suffering a smaller decrease in performance
with realistic genotype failure rates. Neither platform used by
the five reported T2D genome-wide association scans is
exhaustive (for example, rare SNPs and structural variation
are under-represented), but new generation genome-wide
arrays have been designed to be more comprehensive.
 
Four months, five scans, six new T2D loci
 
The field of T2D has been at the forefront of genetic associa-
tion studies for some time, with a recent history of successful
large-scale well-designed candidate gene studies and an emerging
strong collaborative ethos (for example, the International T2D
1q Consortium, formed to carry out fine mapping of the
chromosome 1q linkage peak in eight populations). It remains
impressive that five genome-wide association scans for the
disease have been published in the space of less than 4 months.
These have led to the identification of six novel T2D suscep-
tibility loci.
The five T2D genome-wide association scans published to
date have followed a range of study designs. Sladek 
 
et al
 
. [5],
the first scan to be published, employed two Illumina platforms:
the HumanHap300 chip and the Infinium Human1 array,
which probes approximately 100k gene-centred SNPs. Using a
moderately sized sample set in their primary scan, Sladek 
 
et al
 
.
focused on French T2D cases with at least one affected
first-degree relative (thus enriching for susceptibility allele
frequency), young age at onset and a body mass index (BMI)
less than 30 kg/m
 
2
 
. Upon replication of their most significant
findings in a further set of 5511 individuals, they were the first
to report the now confirmed 
 
SLC30A8
 
 and 
 
HHEX
 
/
 
IDE
 
 genes
as novel T2D susceptibility loci. Further replicating loci in this
French study (
 
EXT2-ALX4
 
 and 
 
LOC387761
 
) have not met
confirmation by the four subsequent scans.
Steinthorsdottir 
 
et al
 
. [6] also used the Illumina Human-
Hap300 array, to genotype a total of 6674 T2D case and
control subjects from Iceland, confirming the 
 
SLC30A8
 
 and
 
HHEX
 
/
 
IDE
 
 findings. Extensive replication studies in samples
from five different populations (Denmark, Philadelphia, the
Netherlands, Hong Kong and West Africa) led to the identifi-
cation of 
 
CDKAL1
 
 as a T2D susceptibility locus. This novel
T2D gene was simultaneously reported by the Steinthorsdottir
 
et al
 
. [6], UK-based [1,2], Scott 
 
et al
 
. [4] and Diabetes Genetics
Initiative (DGI) [3] studies.
In an unprecedented collaboration, the latter three studies
joined forces to combine the findings of both their primary
scans and follow-up endeavours (leading to a total of 32 554
samples), identifying 
 
CDKAL1
 
, 
 
CDKN2A
 
/
 
B
 
, 
 
IGF2BP2
 
 and
 
FTO
 
  as novel T2D susceptibility loci and confirming the
 
SLC30A8
 
 and 
 
HHEX
 
/
 
IDE
 
 associations.
Individually, the UK-based T2D GWAS was carried out as
part of the Wellcome Trust Case Control Consortium (WTCCC)
study, which included approximately 14 000 cases of seven
common diseases (~2000 of which were T2D cases, partly
enriched for younger age at onset and for family history of the
disease) and 3000 shared control subjects, genotyped on the
Affymetrix 500k platform [1]. Interesting findings were subse-
quently followed up in at least 9103 T2D case and control
subjects [2,15]. Scott 
 
et al
 
. [4] genotyped 2335 Finnish T2D
case and control individuals on the HumanHap300 array
and then analysed imputed genotypes HapMap-wide. Imputa-
tion involves the use of phased HapMap CEU data to infer
genotypes at untyped positions. Second stage genotyping was
performed in 2473 further individuals. The DGI employed the
Affymetrix 500k chip to genotype 3077 individuals from
Finland and Sweden in a combination of population- and
family-based samples [3]. Replication studies involved 10 850
T2D case and control subjects.
Tables 1 and 2 summarize the main characteristics of each
primary scan and associated follow-up experiments, respectively.
Upholding the gold standard in association studies, all five
genome-wide association scans included a replication stage,
where the robustness of identified associations was tested.
 
Characteristics of the six robustly replicating 
genome-wide association signals
 
Indirect LD mapping of disease variants is an inherent
characteristic of genome-wide association scans using currently
available defined-content SNP chips. As such, the five published
T2D GWAS have identified six novel, robustly replicating
signals within the limits of resolution afforded by the respective
arrays employed. This makes unequivocal identification of
T2D disease-predisposing genes difficult. Further fine mapping
(by genotyping a dense map of polymorphisms in diverse
populations) and/or extensive resequencing efforts will be
necessary before a single gene can be declared as most likely to
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be causal. Of the six confirmed T2D association signals, four
appear to cluster within specific genes (
 
CDKAL1
 
, 
 
SLC30A8
 
,
 
IGF2BP2
 
, 
 
FTO
 
) and two extend across larger regions (near
 
CDKN2A
 
/
 
B
 
  on chromosome  9 and near 
 
HHEX
 
/
 
IDE
 
  on
chromosome 10).
All six replicating associations were observed at common
sequence variants, i.e. SNPs with relatively high minor allele
frequencies. This is, however, not unexpected, given SNP chip
content and association power limitations brought about by
the sample sizes employed (Table  1). Although we cannot
exhaustively assess the genetic architecture of T2D before
examining variants across the full spectrum of allele frequen-
cies in sufficiently powered studies, it has now become clear
that multiple common variants are certainly part of the picture
and play a role in increasing susceptibility to T2D.
Elucidating the genetic model under which known disease
variants operate can prove a helpful guide for future studies.
With the possible exception of 
 
CDKAL1
 
, all novel T2D loci
currently appear to follow an additive mode of inheritance,
reflecting a linear change of disease risk with each extra allele
copy carried. This observation could, however, prove to be an
artefact of allelic association (LD) and the fact that the truly
causal variant remains to be identified.
The per-allele effect sizes of all six loci were found to be
modest, with odds ratios approximately ranging from 1.1 to
1.2. This is a sobering observation that highlights the need for
large sample sizes if further loci are to be identified at genome-
wide levels of significance (for example, over 11 500 cases and
an equal number of control subjects would be necessary to
detect an effect size of 1.15 with 80% power at 
 
P
 
 = 10
 
–7
 
 for a
common SNP with 20% minor allele frequency).
Phenotype definition can also prove crucial in determining
power to discover disease genes. The 
 
FTO
 
 signal, for instance,
was identified and quickly replicated as part of the UK
Table 1 Primary scan characteristics
Genome-wide 
association scan Platform
Cases
(n)
Control 
subjects (n) Population T2D phenotype
Sladek et al. [5] Illumina HumanHap300 661 614 France Family history of T2D, 
Infinium Human1 AAO < 45 years, BMI < 30 kg/m2
WTCCC [1] Affymetrix 500k 1924 2938 UK Partial enrichment for family history of
T2D, AAO < 65 years
Scott et al. [4] Illumina HumanHap300 1161 1174 Finland Partial enrichment for family history
DGI [3] Affymetrix 500k 1464 1467 Finland, Sweden Partial enrichment for family history
Steinthorsdottir et al. [6] Illumina HumanHap300 1399 5275 Iceland No specific enrichment for family
history, young AAO or BMI
AAO, age at onset; BMI, body mass index; DGI, Diabetes Genetics Initiative; T2D, Type 2 diabetes; WTCCC, Wellcome Trust Case Control 
Consortium.
Table 2 Stage 2/replication study characteristics
Genome-wide 
association follow-up
Cases
(n)
Control 
subjects (n) Population T2D phenotype Confirmed T2D loci reported
Sladek et al. [5] 2617 2894 France BMI < 35 kg/m2 TCF7L2, SLC30A8, HHEX/IDE
Zeggini et al.* [2] 3757 5346 UK Partial enrichment for  TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE, 
AAO < 45 years SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11*
Scott et al.* [1] 1215 1258 Finland No specific enrichment TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE,
SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11*
DGI* [4] 5065 5785 European 
ancestry†
No specific enrichment TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE, 
SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11*
Steinthorsdottir 
et al. [6]
3826 12562 European 
ancestry‡
No specific enrichment TCF7L2, CDKAL1, SLC30A8, HHEX/IDE
1457 986 Hong Kong Partial enrichment for 
AAO < 40 years
865 1106 West Africa Family history of T2D
*The Zeggini et al. [2], Scott et al. [4] and DGI [3] replication studies included meta-analysis of primary scan and stage 2 datasets from each of 
the three studies.
†From Sweden, Poland and the USA.
‡From Denmark, Philadelphia and the Netherlands.
AAO, age at onset; BMI, body mass index; DGI, Diabetes Genetics Initiative; T2D, Type 2 diabetes.
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genome-wide association study [1,2], but was not inde-
pendently observed in any of the other scans. It subsequently
transpired that 
 
FTO
 
 exerts its effect on T2D risk through
adiposity and has since been established as an obesity gene
[15]. Although failure by four of the five scans to identify 
 
FTO
 
as a diabetes gene may be ascribed to sample size differences,
variable phenotype definition (for example, in Sladek 
 
et al
 
. [5],
Tables 1 and 2) and case-control matching for BMI (DGI
scan [3]) could have led to significant dilution of the signal,
rendering it undetectable.
 
Insights into T2D aetiology
 
Genome-wide association studies do not rely on gene candidacy
assessment and offer the hope of gaining insights into disease
aetiopathology. The five T2D GWAS have achieved just that.
But why had the six new T2D loci escaped the radar of tradi-
tional approaches and what insights into T2D aetiology have
we gained?
The 
 
HHEX
 
/
 
IDE
 
 signal resides under a well-replicated T2D
peak of linkage (a few megabases away from 
 
TCF7L2
 
, on
chromosome 10q). However, the associated variants do not
possess characteristics (in terms of allele frequency and effect
size) that would explain the linkage signal observed. Nevertheless,
 
IDE
 
 (coding for insulin degrading enzyme) has been studied as
a T2D candidate gene in the past, giving rise to inconsistent
associations [16–18]. The 
 
IDE
 
 story highlights how important
comprehensive capture of sequence variation is, before any
gene can be discounted. 
 
HHEX
 
 (homeobox, haematopoietically
expressed) encodes a transcription factor important for
pancreatic development [19,20] and (retrospectively) consti-
tutes a strong candidate. The chr10q T2D signal in this region
also extends over 
 
KIF11
 
, encoding kinesin interacting factor.
Recent data suggest that T2D risk variants within this region
are associated with reduced pancreatic 
 
β
 
-cell function [21].
 
IGF2BP2
 
, coding for insulin-like growth factor 2 mRNA
binding protein 2, resides in the vicinity of the chr3q linkage
peak for T2D and related traits and, although a good candidate,
had not previously been the focus of a T2D genetic association
study. The genome-wide association signal spans the promoter
and first two exons of this gene. IGF2BP2 binds the 3
 
′
 
 UTR of
the insulin-like growth factor 2 (
 
IGF2
 
) transcript and regulates
 
IGF2
 
 translation [22]. IGF2 is involved in cell proliferation,
differentiation and stimulation of insulin action.
The chr9p signal is idiosyncratic and will undoubtedly
require extensive rounds of fine mapping and resequencing
before the causal functional unit(s) can be determined. The
most strongly associated SNPs reside 3
 
′
 
  of 
 
CDKN2A
 
  and
 
CDKN2B
 
 in a small region with no characterized genes,
delineated by recombination hotspots. Interestingly, a strong
signal for heart disease (driven by SNPs independent of those
implicated in T2D) also resides in this region [1,23,24]. It is
possible that this overlap may reflect common aetiopathogenic
pathways. 
 
CDKN2B 
 
and 
 
CDKN2A 
 
code for p15
 
INK4b
 
 and
p16
 
INK4a
 
, respectively. p16
 
INK4a
 
 plays a role in pancreatic
B-cell replication by inhibiting CDK4 (cyclin-dependent
kinase 4) [25–27]. Evidence from murine models also demon-
strates a central role in islet proliferation for both 
 
CDKN2A
 
and 
 
CDKN2B
 
 [28,29].
The 
 
CDKAL1
 
 [cyclin-dependent kinase 5 (CDK5) regula-
tory subunit associated protein 1-like 1] signal is centred in
intron 5 of the gene (highly expressed in human pancreas and
skeletal muscle [2]). Although the gene product function has
not yet been characterized, protein homology to CDK5
regulatory subunit-associated protein  1 indicates a role in
CDK5 inhibition. CDK5 is important in the glucotoxic loss of
B-cell function [30,31]. T2D susceptibility-associated varia-
tion in 
 
CDKAL1 
 
has been shown to confer risk through
reduced insulin secretion [6,21]. Specifically, Steinthorsdottir
 
et al
 
. [6] showed that the insulin response for carriers of two
copies of the risk allele was 22% lower than for heterozygotes
or non-carriers.
The T2D-associated SNP in 
 
SLC30A8
 
 is a non-synonymous
Arg
 
→Trp variant. SLC30A8 codes for a pancreatic islet-
specific zinc transporter and is involved in insulin biosynthesis,
maturation and storage by mediating zinc accumulation in
intracellular insulin-containing vesicles. The SLC30A8 T2D
variant has also been found to be associated with decreased
insulin secretion [6].
FTO, although identified through a T2D GWAS, has already
been established as a robustly replicating obesity locus [15,32].
However, the mechanism through which FTO might exert
its function remains unknown. It is widely expressed, with
pronounced transcription levels in the brain [15]. Clearly, our
understanding of its mode of action is still in its infancy.
Impact on diabetes care
The five published T2D genome-wide association scans signify
huge strides forward for the field and their findings are
expected to make an impact on diabetes care. They offer the
potential to explore new biology and develop novel treatments,
following the examples of PPARG and KCNJ11, where
therapeutic agents (thiazolidinediones and sulphonylureas,
respectively) and genes are closely associated. There are
undoubtedly many exciting lessons on diabetes biology to be
learnt from the six new susceptibility loci. Overall, the scales
appear to tip towards aetiological pathways involved in
pancreatic B-cell development, function and regeneration.
Interdisciplinary endeavours involving genetic, functional and
physiological studies will now be necessary to take this new
knowledge further.
The associated variants could also have diagnostic and
prognostic potential. Scott et al. [4] calculated a fourfold
variation in T2D risk between the carriers of all known risk
alleles and non-carriers. However, as the SNPs have common
frequencies and moderate effect sizes, their immediate diagnostic
potential is reduced. Their combined predictive power is also
currently too small to be clinically useful ([33]; M. N. Weedon,
personal communication). It is possible that rarer, more
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penetrant variants will be of higher predictive value, but these
remain to be identified and would be expected to affect a
smaller proportion of T2D patients. In addition, the methodology
by which to unearth such sequence variation is not yet
optimized. However, rapid advances in resequencing technologies
and analytical approaches are poised to make this possible
in the near future.
Taking the next steps forward
Replication of the major GWAS findings in diverse popula-
tions, fine mapping of the association signals and extensive
resequencing of implicated genes will now form the next steps
in the field of T2D genetics. But what about signals that have
not yet been unearthed? Emerging imputation approaches
will make a more comprehensive assessment of human genome
variation possible. However, proactive collaborative efforts
will be necessary in order to attain sufficient power to detect
and replicate novel T2D genes. Functional and physiological
studies in well-characterized cohorts will ultimately provide us
with clear answers and pave the way for meaningful translation
of this research into diabetes care.
Glossary
Single nucleotide polymorphism (SNP)
A single nucleotide polymorphism is a single-base change in
the human genome sequence. SNPs are the commonest form
of human genome variation and occur every 100–300 base
pairs.
Linkage disequilibrium (LD)
Linkage disequilibrium or allelic association is the occurrence
of alleles together on the same chromosome more often than
expected based on their allele frequencies.
Untranslated region (UTR)
Untranslated regions are portions of mRNA that do not code
for proteins. UTRs contain sequence important for translation
regulation and mRNA stability.
High-throughput genotyping
High-throughput, highly parallel genotyping assays are highly
automated and allow rapid processing of a large number of
samples. Automated software tools are used for the assign-
ment of genotypes.
Case-control association study
In the case-control association study design, sequence variant
frequencies are compared between a sample of affected
individuals (cases) and an appropriate control group.
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